Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Pediatric Moderately to Severely Active Crohn’s Disease
2023-504978-38-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission at Induction Week 8. Started Aug 2023; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-504978-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504978-38-00.